Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Solanocapsine is a steroidal alkaloid naturally found in the Jerusalem cherry (*Solanum pseudocapsicum*). It has been identified as a selective synthetic lethal inducer in BRCA2-deficient cancer cells. Chemoproteomic profiling revealed that solanocapsine acts as an inhibitor of deoxycytidine kinase (dCK), a rate-limiting enzyme in the deoxyribonucleoside salvage pathway. By inhibiting dCK, solanocapsine restricts the nucleotide supply during mitosis, selectively triggering cell death in BRCA2-deficient contexts. While solanocapsine itself is a toxic alkaloid, it serves as a chemical starting point for the development of more potent dCK-inhibiting analogs for the treatment of BRCA2-deficient malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on solanocapsine.